Public Release: 

Antibody-drug conjugate shows efficacy against cell surface protein in neuroblastoma

CHOP researchers: This first-in-class immunotherapeutic approach could spawn new treatment options for neuroblastoma and other high-mortality childhood cancers

Children's Hospital of Philadelphia

IMAGE

IMAGE: Yael Mosse, M.D., is a pediatric oncologist and researcher at Children's Hospital of Philadelphia. view more 

Credit: Children's Hospital of Philadelphia

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

The researchers published their findings today in Science Translational Medicine.

"If there is an ultimate 'bad guy' of neuroblastoma cell surface proteins--present on most tumors, but not on healthy tissues, and also vulnerable to immunotherapeutic targeting--this just may be it," said study leader Yael Mossé, MD, a pediatric oncologist and researcher at Children's Hospital of Philadelphia (CHOP). "In 2008, we discovered mutations in the anaplastic lymphoma kinase (ALK) gene as the major cause of the inherited form of neuroblastoma and showed that these same mutations are present in about 14 percent of neuroblastoma tumors from patients with the most aggressive form of this disease. This established ALK as a druggable target in neuroblastoma and provided the rationale for the clinical development of ALK inhibition therapy. We now show that native ALK (in the absence of a mutation) is present on most neuroblastoma tumors, providing us with an exciting opportunity to target ALK in the majority of patients."

Neuroblastoma, a pediatric cancer of the developing peripheral nervous system that usually occurs as a solid tumor in a child's chest or abdomen, is the most common cancer in infants, and accounts for more than 10 percent of all childhood cancer deaths. Children with the high-risk form of the disease continue to have a poor prognosis, despite intensive drug therapy.

Mossé, along with other scientists in her lab, demonstrated that the ALK protein appears on the surface of most neuroblastoma cells and is not detectable on normal cells, indicating that ALK is a useful target for immunotherapy. Researchers worked with pharmaceutical colleagues to weaponize an antibody-drug conjugate (ADC), one of a rapidly growing class of anticancer agents. That ADC, called CDX-0125-TEI, combines a specific monoclonal antibody engineered to recognize ALK with a potent chemotherapy drug--an alkylating agent called thienoindole (TEI).

In cell cultures and animal models of neuroblastoma, the ADC-ALK approach killed neuroblastoma cells, with no discernible toxicity to healthy cells. "The goal of this approach is to harness the presence of ALK to precisely deliver a poison only to the cancer cell, without harming the healthy surrounding cells," said Mossé.

"This study is proof of concept that the ALK protein is a good immunotherapy target and, as we optimize this approach for the clinic, has the potential to be useful for the majority of aggressive neuroblastomas and to minimize the harsh consequences of therapy," said Mossé.

She added, "In addition, our research could have great relevance for other cutting-edge immunotherapeutic strategies, such as CAR T-cell therapy, that harness the immune system to kill cancer, and is currently showing tremendous efficacy in children with leukemia. Our new data support clinical development of an immunotherapy drug not just for neuroblastoma, but for other hard-to-cure childhood cancers expressing the ALK gene, including rhabdomyosarcomas."

Over decades, CHOP clinicians and researchers have built one of the world's leading programs in neuroblastoma. The Mossé laboratory is focused on the underlying molecular mechanisms by which ALK gene activation contributes to development and progression of pediatric neuroblastoma, and to identify targeted, less toxic cancer therapies for children with ALK-mediated disease.

###

Funding for this research was provided by the U.S. Department of Defense (award W81XWH-12-1-0486) with additional support from Kolltan Pharmaceuticals, Solving Kids' Cancer and Braden's Hope Foundation.

Yael P. Mossé, et al, "An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma," Science Translational Medicine, online March 13, 2019.

Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.